"Vancomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
| Descriptor ID |
D014640
|
| MeSH Number(s) |
D09.400.420.925 D12.644.233.925
|
| Concept/Terms |
Vancocin- Vancocin
- Vancocin HCl
- Vancomycin Lilly
- Vancocine
|
Below are MeSH descriptors whose meaning is more general than "Vancomycin".
Below are MeSH descriptors whose meaning is more specific than "Vancomycin".
This graph shows the total number of publications written about "Vancomycin" by people in this website by year, and whether "Vancomycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 3 | 6 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 2 | 4 |
| 2006 | 4 | 1 | 5 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 2 | 4 |
| 2009 | 4 | 0 | 4 |
| 2011 | 2 | 4 | 6 |
| 2012 | 2 | 6 | 8 |
| 2013 | 7 | 1 | 8 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 6 | 7 |
| 2017 | 5 | 6 | 11 |
| 2018 | 5 | 2 | 7 |
| 2019 | 4 | 1 | 5 |
| 2020 | 5 | 3 | 8 |
| 2021 | 1 | 3 | 4 |
| 2022 | 3 | 5 | 8 |
| 2023 | 0 | 1 | 1 |
| 2024 | 4 | 2 | 6 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vancomycin" by people in Profiles.
-
Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
-
Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients. Crit Care Explor. 2024 Oct 01; 6(10):e1159.
-
Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024 07 19; 79(1):15-21.
-
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Cancer Discov. 2024 Jul 01; 14(7):1161-1175.
-
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
-
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium. Aliment Pharmacol Ther. 2024 05; 59(10):1236-1247.
-
Vancomycin nephrotoxicity: A comprehensive clinico-pathological study. PLoS One. 2024; 19(3):e0295136.
-
Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0162123.
-
Impact of oral vancomycin treatment duration on rate of Clostridioides difficile recurrence in patients requiring concurrent systemic antibiotics. Infect Control Hosp Epidemiol. 2024 Jun; 45(6):717-725.
-
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.